- Email: [email protected]
- Telephone: +1 212 474 1430
- Fax: +1 212 474 3700
- Website: http://www.cravath.com
Partner at Cravath, Swaine & Moore LLP
David R Marriott is a partner in Cravath, Swaine & Moore LLP’s litigation department. Mr Marriott has tried, argued and litigated IP and other complex commercial matters in both state and federal courts across the country. He has represented a number of major pharmaceutical and technology companies, including Mylan, IBM, Novartis, Alcon Laboratories, Qualcomm, Bristol-Myers Squibb and AT&T.
Mr Marriott currently represents Qualcomm in antitrust and patent infringement litigation against Apple, including before the US International Trade Commission, and IBM in a lawsuit brought by The SCO Group concerning the UNIX and Linux operating systems.
Mr Marriott recently represented Merck Sharp & Dohme as plaintiff in three separate patent infringement actions seeking to enjoin the marketing and sale of generic versions of Merck’s antifungal agent, Noxafil®, and Juno Therapeutics in a lawsuit filed by City of Hope alleging that Juno violated an exclusive licence agreement to certain City of Hope patents. He also represented Mylan in a patent infringement suit over Teva Pharmaceuticals’ development of a generic form of Mylan’s respiratory drug Perforomist®. Following a seven-day bench trial, the court upheld the validity of Mylan’s patents and enjoined Teva from marketing a generic version of the drug until Mylan’s patents expire. The decision was affirmed on appeal.
Mr Marriott is a fellow of the American College of Trial Lawyers, an adjunct professor at New York University School of Law and a lecturer in law at Columbia University School of Law. He has been recognised as a leading lawyer by numerous professional organisations, including Benchmark Litigation, Legal 500 and Lawdragon.
Mr Marriott received his JD from New York University School of Law in 1994 and his BA from Brigham Young University in 1991.